This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
The company’s lead candidate Tenapanor is a targeted, small molecule therapy currently under FDA review. As the pandemic surged this year, the disruption of healthcare systems posed a significant challenge for patients receiving kidney care. Patients who undergo dialysis are some of the most fragile.
Plecanatide : This is one of the newest medications for IBS-C that has been approved by the FDA. Plecanatide is recommended by the ACG for overall symptomatic improvement in IBS-C patients. Lubiprostone : This medication is often recommended for symptomatic improvement in IBS-C patients. J Clin Endocrinol Metab. doi:10.1210/jc.2007-0606
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
2007 
104 
Let's personalize your content